lenalidomide has been researched along with mycophenolic acid in 6 studies
| Studies (lenalidomide) | Trials (lenalidomide) | Recent Studies (post-2010) (lenalidomide) | Studies (mycophenolic acid) | Trials (mycophenolic acid) | Recent Studies (post-2010) (mycophenolic acid) |
|---|---|---|---|---|---|
| 3,532 | 725 | 2,850 | 9,029 | 1,506 | 3,772 |
| Protein | Taxonomy | lenalidomide (IC50) | mycophenolic acid (IC50) |
|---|---|---|---|
| Inosine-5'-monophosphate dehydrogenase 2 | Homo sapiens (human) | 0.1496 | |
| Glutamate receptor 1 | Rattus norvegicus (Norway rat) | 0.014 | |
| Glutamate receptor 2 | Rattus norvegicus (Norway rat) | 0.014 | |
| Glutamate receptor 3 | Rattus norvegicus (Norway rat) | 0.014 | |
| Glutamate receptor 4 | Rattus norvegicus (Norway rat) | 0.014 | |
| Inosine-5'-monophosphate dehydrogenase 1 | Homo sapiens (human) | 0.0772 | |
| Sodium-dependent serotonin transporter | Rattus norvegicus (Norway rat) | 0.011 | |
| Inosine-5'-monophosphate dehydrogenase | Cryptococcus neoformans var. neoformans JEC21 | 0.12 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bonsmann, G; Kuhn, A; Ruland, V | 1 |
| Bruijnen, CP; Cornelisse, PB; Cornelissen, JJ; Emmelot, M; Huisman, C; Huls, G; Janssen, JJ; Kersten, MJ; Kneppers, E; Lokhorst, HM; Meijer, E; Minnema, MC; Mutis, T; Sonneveld, P; van der Holt, B; Zweegman, S | 1 |
| Aberer, E; Bata-Csörgő, Z; Caproni, M; Dreher, A; Frances, C; Gläser, R; Klötgen, HW; Kuhn, A; Landmann, A; Marinovic, B; Nyberg, F; Olteanu, R; Ranki, A; Szepietowski, JC; Volc-Platzer, B | 1 |
| Bunnapradist, S; Danovitch, G; Huang, E; Lum, EL; Pham, T | 1 |
| Nutan, F; Ortega-Loayza, AG | 1 |
3 review(s) available for lenalidomide and mycophenolic acid
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Cutaneous lupus erythematosus: update of therapeutic options part II.
Topics: Algorithms; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Azathioprine; Clofazimine; Cyclophosphamide; Cyclosporine; Dapsone; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Interferon-alpha; Isoxazoles; Leflunomide; Lenalidomide; Lupus Erythematosus, Cutaneous; Methotrexate; Mycophenolic Acid; Retinoids; Rituximab; Thalidomide; Tumor Necrosis Factor-alpha | 2011 |
Cutaneous Lupus: A Brief Review of Old and New Medical Therapeutic Options.
Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal; Antimalarials; Calcineurin Inhibitors; Dapsone; Humans; Immunologic Factors; Lenalidomide; Lupus Erythematosus, Cutaneous; Methotrexate; Mycophenolic Acid; Retinoids; Thalidomide | 2017 |
1 trial(s) available for lenalidomide and mycophenolic acid
| Article | Year |
|---|---|
Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial.
Topics: Acute Disease; Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Cyclophosphamide; Cyclosporine; Disease-Free Survival; Drug Eruptions; Feasibility Studies; Female; Graft vs Host Disease; Hematologic Diseases; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Immunosuppressive Agents; Lenalidomide; Lymphocyte Count; Male; Melphalan; Middle Aged; Multiple Myeloma; Mycophenolic Acid; Prospective Studies; Remission Induction; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Whole-Body Irradiation | 2011 |
2 other study(ies) available for lenalidomide and mycophenolic acid
| Article | Year |
|---|---|
S2k guideline for treatment of cutaneous lupus erythematosus - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV).
Topics: Adrenal Cortex Hormones; Antimalarials; Biological Products; Calcineurin Inhibitors; Consensus; Dapsone; Humans; Immunosuppressive Agents; Lenalidomide; Lupus Erythematosus, Cutaneous; Methotrexate; Mycophenolic Acid; Practice Guidelines as Topic; Retinoids; Thalidomide | 2017 |
Acute Kidney Allograft Rejection Precipitated by Lenalidomide Treatment for Multiple Myeloma.
Topics: Adrenal Cortex Hormones; Aged; Antilymphocyte Serum; Deprescriptions; Female; Graft Rejection; Humans; Immunoglobulins, Intravenous; Immunologic Factors; Immunosuppressive Agents; Kidney; Kidney Transplantation; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Mycophenolic Acid; Polycystic Kidney, Autosomal Dominant; Tacrolimus; Thalidomide | 2017 |